论文部分内容阅读
目的观察普米克令舒治疗慢性阻塞性肺疾病急性加重期(acute exacerbation of chronic obstructive pul monary disease,AECOPD)的临床疗效,比较其疗效与全身应用糖皮质激素的差异。方法选取66例AECOPD病人,随机分为两组,观察组31例病人使用普米克令舒(吸入布地奈德悬液)2mg每日2次雾化吸入,共8天,对照组35例病人使用甲基强的松龙40mg每日一次静点,5天,后改为20mg每日1次静点共3天,分别比较治疗前、后病人临床症状(包括咳嗽、咳痰量、喘息气短),肺功能及血气分析。结果雾化吸入普米克令舒可以明显改善AECOPD患者的临床症状、肺功能及血气分析指标,且与甲基强的松龙治疗效果比较,统计学上没有明显的差异,且不良反应少。结论雾化吸入普米克令舒对于治疗AECOPD患者有很好的临床疗效,并且与全身应用糖皮质激素相比不良反应少,安全性高,尤其是对老年患者,具有较高的临床应用价值。
Objective To observe the clinical efficacy of pulmicort resuscitation in the treatment of acute exacerbation of chronic obstructive pulmonar monary disease (AECOPD), and to compare the differences between the curative effect and systemic glucocorticoid therapy. Methods Sixty-six patients with AECOPD were randomly divided into two groups. In the observation group, 31 patients received pulmonicate (inhalation of budesonide suspension) 2 mg twice a day for 8 days and 35 patients in the control group Methylprednisolone 40mg intravenous once a day, 5 days, later changed to 20mg once a day for a total of three days of static point, were compared before and after treatment of patients with clinical symptoms (including cough, sputum volume, shortness of breath) , Lung function and blood gas analysis. Results The inhalation of pulmicort respules significantly improved the clinical symptoms, lung function and blood gas analysis indexes of patients with AECOPD. Compared with the treatment of methylprednisolone, there was no statistically significant difference and less adverse reactions. Conclusion Pulmicort respules inhalation has a good clinical efficacy in the treatment of patients with AECOPD, and compared with the systemic glucocorticoid less adverse reactions, high safety, especially for elderly patients, has a high clinical value.